ORKAMBI

October 12, 2015November 5, 2015

Vertex Presents Key Findings on Kalydeco, Orkambi & Experimental CF Therapies at NACFC

Cystic Fibrosis, News

A series of new updates and future development plans were recently announced by Vertex regarding its approved and candidate drugs to treat Cystic fibrosis (CF). The announcements, made at the 29th Annual ... Read more

September 28, 2015September 28, 2015

CHMP Issues Positive Recommendation for ORKAMBI and KALYDECO in the EU

News

Biotechnology company Vertex Pharmaceuticals, Inc. recently announced that the European Union Committee for Medicinal Products for Human Use (CHMP) has released a positive opinion and recommendation for Marketing Authorization of breakthrough ... Read more

September 23, 2015November 5, 2015

Concert Pharma Reports Phase 1 Results of Experimental CF Therapy CTP-656

Cystic Fibrosis, News

Concert Pharma, a biotechnology company utilizing deuterium chemistry to discover and develop innovative drug products that can address unmet medical needs, recently announced positive results from its Phase 1 single ascending dose study ... Read more

July 6, 2015November 5, 2015

FDA Approves Vertex’s New Cystic Fibrosis Therapy Orkambi

Cystic Fibrosis, News

The U.S. Food and Drug Administration (FDA) approved Vertex’s new drug Orkambi for treatment of cystic fibrosis (CF) on July 2, 2015. This is the first medication specifically intended for ... Read more

June 12, 2015November 5, 2015

Vertex Presents Data at European Cystic Fibrosis Society (ECFS) Conference on Orkambi Combo Therapy

Cystic Fibrosis, News

Vertex Pharmaceuticals recently announced results from its PROGRESS long-term extension trial that is evaluating the efficacy of the ORKAMBI (lumacaftor/ivacaftor) investigational regimen in patients with cystic fibrosis (CF). Cystic Fibrosis patients aged ... Read more

May 13, 2015November 5, 2015

Vertex’s New CF Drug Combo Receives Positive FDA Recommendation

Cystic Fibrosis, News

The U.S. Food and Drug Administration (FDA) has issued a positive evaluation of ORKAMBI (lumacaftor/ivacaftor) as a recommended treatment for cystic fibrosis (CF) patients 12 years and older with two copies of the F508del mutation ... Read more